VanEck Biotech ETF
BBH
90 hedge funds and large institutions have $167M invested in VanEck Biotech ETF in 2015 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 29 reducing their positions, and 9 closing their positions.
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
8% more funds holding
Funds holding: 83 → 90 (+7)
2% less call options, than puts
Call options by funds: $4.19M | Put options by funds: $4.28M
21% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 29
21.1% less ownership
Funds ownership: 45.23% → 24.14% (-21%)
43% less capital invested
Capital invested by funds: $294M → $167M (-$127M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$5.67M |
| 2 |
LPL Financial
San Diego,
California
|
+$3.92M |
| 3 |
JP Morgan Chase
New York
|
+$3.91M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.87M |
| 5 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
+$2.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$147M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$13.6M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.49M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.08M |
| 5 |
HF
HRT Financial
New York
|
-$1.84M |
BBH Hedge Fund Activity: Q4 2015 in Review
90 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q4 2015, worth a combined $167M — down 43% from $294M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new BBH positions and 9 closed out — a net gain of 7 holders — while 23 added to existing stakes and 29 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $5.67M. The largest seller was Goldman Sachs, cutting an estimated $147M.
- 90 institutional investors held VanEck Biotech ETF (BBH) as of Q4 2015, up from 83 in Q3 2015.
- Funds reported $167M of VanEck Biotech ETF stock for Q4 2015, down 43% quarter-over-quarter.
- 16 funds opened new VanEck Biotech ETF positions in Q4 2015 and 9 closed out, a net change of +7 holders.
- The largest VanEck Biotech ETF buyer in Q4 2015 was Morgan Stanley, an estimated $5.67M added.
- The largest VanEck Biotech ETF seller in Q4 2015 was Goldman Sachs, an estimated $147M sold.
Based on aggregated 13F filings for Q4 2015.